Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3491Neoplasms 2738Prostatic Neoplasms 1580Colorectal Neoplasms 1243Lung Neoplasms 1184Motor Activity 763Head and Neck Neoplasms 619Pancreatic Neoplasms 600Colonic Neoplasms 586Uterine Cervical Neoplasms 563Carcinoma, Non-Small-Cell Lung 559Carcinoma, Hepatocellular 556Rectal Neoplasms 514Stomach Neoplasms 490Brain Neoplasms 435Anxiety Disorders 400Ovarian Neoplasms 396Pain 375Esophageal Neoplasms 347Neoplasm Metastasis 340Polycystic Ovary Syndrome 339Fatigue 323Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 285Multiple Myeloma 281Endometrial Neoplasms 262Lymphoma 257Hematologic Neoplasms 250

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × Hormone Refractory Prostate Cancer × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡